Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Invested Capital (2020 - 2023)

Terns Pharmaceuticals' Invested Capital history spans 4 years, with the latest figure at $258.4 million for Q3 2023.

  • For Q3 2023, Invested Capital rose 40.68% year-over-year to $258.4 million; the TTM value through Sep 2023 reached $258.4 million, up 40.68%, while the annual FY2022 figure was $276.9 million, 72.76% up from the prior year.
  • Invested Capital reached $258.4 million in Q3 2023 per TERN's latest filing, down from $274.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $287.7 million in Q1 2023 to a low of -$119.8 million in Q3 2020.
  • Average Invested Capital over 4 years is $122.5 million, with a median of $172.2 million recorded in 2021.
  • Peak YoY movement for Invested Capital: skyrocketed 290.51% in 2021, then dropped 24.33% in 2022.
  • A 4-year view of Invested Capital shows it stood at -$104.6 million in 2020, then skyrocketed by 253.31% to $160.3 million in 2021, then surged by 72.76% to $276.9 million in 2022, then dropped by 6.69% to $258.4 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Invested Capital are $258.4 million (Q3 2023), $274.2 million (Q2 2023), and $287.7 million (Q1 2023).